Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]

Jessica L. Dunne; Sarah J. Richardson; Mark A. Atkinson; Maria E. Craig; Knut Dahl-Jørgensen; Malin Flodström-Tullberg; Heikki Hyöty; Richard E. Lloyd; Noel G. Morgan; Alberto Pugliese

doi:10.1007/s00125-019-4873-6

Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]

Jessica L. Dunne, Sarah J. Richardson, Mark A. Atkinson, Maria E. Craig, Knut Dahl-Jørgensen, Malin Flodström-Tullberg, Heikki Hyöty, Richard E. Lloyd, Noel G. Morgan, Alberto Pugliese

Medicine

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	1100-1103
Number of pages	4
Journal	Diabetologia
Volume	62
Issue number	6
DOIs	https://doi.org/10.1007/s00125-019-4873-6
State	Published - Jun 1 2019

Keywords

Antiviral agents
Clinical trials
DiViD
Enterovirus
Islet
nPOD

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s00125-019-4873-6

Cite this

Dunne, J. L., Richardson, S. J., Atkinson, M. A., Craig, M. E., Dahl-Jørgensen, K., Flodström-Tullberg, M., Hyöty, H., Lloyd, R. E., Morgan, N. G., & Pugliese, A. (2019). Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. Diabetologia, 62(6), 1100-1103. https://doi.org/10.1007/s00125-019-4873-6

Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. / Dunne, Jessica L.; Richardson, Sarah J.; Atkinson, Mark A.; Craig, Maria E.; Dahl-Jørgensen, Knut; Flodström-Tullberg, Malin; Hyöty, Heikki; Lloyd, Richard E.; Morgan, Noel G.; Pugliese, Alberto.

In: Diabetologia, Vol. 62, No. 6, 01.06.2019, p. 1100-1103.

Research output: Contribution to journal › Letter › peer-review

Dunne, JL, Richardson, SJ, Atkinson, MA, Craig, ME, Dahl-Jørgensen, K, Flodström-Tullberg, M, Hyöty, H, Lloyd, RE, Morgan, NG & Pugliese, A 2019, 'Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]', Diabetologia, vol. 62, no. 6, pp. 1100-1103. https://doi.org/10.1007/s00125-019-4873-6

Dunne, Jessica L. ; Richardson, Sarah J. ; Atkinson, Mark A. ; Craig, Maria E. ; Dahl-Jørgensen, Knut ; Flodström-Tullberg, Malin ; Hyöty, Heikki ; Lloyd, Richard E. ; Morgan, Noel G. ; Pugliese, Alberto. / Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. In: Diabetologia. 2019 ; Vol. 62, No. 6. pp. 1100-1103.

@article{0b9fc4a38d454b48bb698995a30d891a,

title = "Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]",

keywords = "Antiviral agents, Clinical trials, DiViD, Enterovirus, Islet, nPOD",

author = "Dunne, {Jessica L.} and Richardson, {Sarah J.} and Atkinson, {Mark A.} and Craig, {Maria E.} and Knut Dahl-J{\o}rgensen and Malin Flodstr{\"o}m-Tullberg and Heikki Hy{\"o}ty and Lloyd, {Richard E.} and Morgan, {Noel G.} and Alberto Pugliese",

note = "Funding Information: Funding Work in the authors{\textquoteright} laboratories is supported by the South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grants to KD-J and MF-T), the Swedish Child Diabetes Foundation (grant to MF-T), the Swedish Research Council (grant to MF-T), and by the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 261441 PEVNET. Some of the authors (AP, SJR, NGM, HH, MAA, REL and MF-T) are supported by JDRF 3-SRA-2017-492-A-N, which funds the nPOD Virus Group in collaborative studies of virus infections in the pancreas with type 1 diabetes. Studies in the Exeter laboratory were supported by a JDRF-CDA award (5-CDA-2014-221-A-N to SJR), and by grant support from MRC (MR/P010695/1) and Diabetes UK (15/0005364) to SJR and NGM. MEC is supported by an Australian National Health and Medical Research Council (NHMRC) Practitioner fellowship [APP1045777] Duality of interest HH is a shareholder and member of the Board of Vactech Ltd., which develops picornavirus vaccines. HH and MF-T serve on the scientific advisory board of Provention Bio Inc., which is developing an enterovirus vaccine.",

year = "2019",

month = jun,

day = "1",

doi = "10.1007/s00125-019-4873-6",

language = "English (US)",

volume = "62",

pages = "1100--1103",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]

AU - Dunne, Jessica L.

AU - Richardson, Sarah J.

AU - Atkinson, Mark A.

AU - Craig, Maria E.

AU - Dahl-Jørgensen, Knut

AU - Flodström-Tullberg, Malin

AU - Hyöty, Heikki

AU - Lloyd, Richard E.

AU - Morgan, Noel G.

AU - Pugliese, Alberto

N1 - Funding Information: Funding Work in the authors’ laboratories is supported by the South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grants to KD-J and MF-T), the Swedish Child Diabetes Foundation (grant to MF-T), the Swedish Research Council (grant to MF-T), and by the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 261441 PEVNET. Some of the authors (AP, SJR, NGM, HH, MAA, REL and MF-T) are supported by JDRF 3-SRA-2017-492-A-N, which funds the nPOD Virus Group in collaborative studies of virus infections in the pancreas with type 1 diabetes. Studies in the Exeter laboratory were supported by a JDRF-CDA award (5-CDA-2014-221-A-N to SJR), and by grant support from MRC (MR/P010695/1) and Diabetes UK (15/0005364) to SJR and NGM. MEC is supported by an Australian National Health and Medical Research Council (NHMRC) Practitioner fellowship [APP1045777] Duality of interest HH is a shareholder and member of the Board of Vactech Ltd., which develops picornavirus vaccines. HH and MF-T serve on the scientific advisory board of Provention Bio Inc., which is developing an enterovirus vaccine.

PY - 2019/6/1

Y1 - 2019/6/1

KW - Antiviral agents

KW - Clinical trials

KW - DiViD

KW - Enterovirus

KW - Islet

KW - nPOD

UR - http://www.scopus.com/inward/record.url?scp=85064810449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064810449&partnerID=8YFLogxK

U2 - 10.1007/s00125-019-4873-6

DO - 10.1007/s00125-019-4873-6

M3 - Letter

C2 - 31016358

AN - SCOPUS:85064810449

VL - 62

SP - 1100

EP - 1103

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 6

ER -

Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this